BIO stock forecast · rev $651.0M
BIO (BIO) common stock.
This BIO forecast page states what the cached financials imply — not a price target and not a guarantee. BIO outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
The near-term path: Revenue was up 9.9% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
BIO currently screens at market cap $0. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next BIO 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the BIO stock page.
Not investment advice.